Buccal and sublingual cannabinoid formulations and method of making the same
A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments.
1. A troche for treating a condition selected from the group consisting of Alzheimer's disease, dementia, inflammatory bowel disease, irritable bowel syndrome, migraine headaches, and insomnia consisting essentially of therapeutically effective amounts of a cannabis extract, polyethylene glycol, and Luo Han Guo powder.
2. The troche of claim 1 , further consisting essentially of an essential oil selected from the group consisting of peppermint, sweet orange, ginger, tangerine and mango, and combinations thereof.
3. The troche of claim 1 , wherein said polyethylene glycol is selected from the group consisting of polyethylene glycol 1450 and polyethylene glycol 1500.
4. The troche of claim 1 , wherein the cannabis extract has a ratio of cannabidiol to tetrahydrocannabinol in a range of 24000:1 to 1:24000.
5. The troche of claim 1 , wherein said cannabis extract consists essentially of one or more of the following: (i) Delta-9 Tetrahydrocannabinol in the decarboxylated form; (ii) Tetrahydrocannabinolic acid in the non-decarboxylated form; (iii) Cannabidiol; (iv) Cannabidiol in combination with Delta-9 Tetrahydrocannabinol in a 0.001:1 to 53:1 ratio of decarboxylated and non-decarboxylated forms of Delta-9 Tetrahydrocannabinol; and (v) Delta-8 Tetrahydrocannabinol.
6. The troche of claim 1 , wherein the cannabis extract has a cannabidiol concentration of 99%-99.9%.
7. The troche of claim 1 , wherein the cannabis extract consists essentially of a compound selected from the group consisting of cannabinoids, terpenes and flavonoids and combinations thereof.